SCHEMBL15635166

SCHEMBL15635166

Cc1[nH]c2ncccc2c1Nc1nccc2ccncc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 3/20 0.45
LATS2 Q9NRM7 2/20 0.44
GRM4 Q14833 1/20 0.39
WNT3A P56704 1/20 0.39
EIF2AK2 P19525 2/20 0.37
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
CDK5 Q00535 1/20 0.36
DYRK1A Q13627 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
CYP2A6 P11509 1/20 0.34
AURKA O14965 1/20 0.34
PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12501126 0.91 LATS1 (0.47) LATS1LATS2GRM4EIF2AK2CLK1
SCHEMBL15635356 0.84 LATS1 (0.40) LATS1LATS2GRM4WNT3ACLK1
SCHEMBL12501058 0.73 IKBKE (0.46) LATS1LATS2CDK5DYRK1ACDK5R1
SCHEMBL878757 0.73 AURKA (0.44) GRM4EIF2AK2CCNB2CDK1CCNB1
SCHEMBL12501053 0.69 LATS1 (0.53) LATS1LATS2EIF2AK2CLK1CLK2
SCHEMBL15634807 0.69 LATS1 (0.53) LATS1
SCHEMBL27692880 0.68 LATS1 (0.47) LATS1LATS2WNT3ACLK1DYRK1A
SCHEMBL15397134 0.67 KDM4E (0.46) LATS1LATS2EIF2AK2CCNB2CDK1
SCHEMBL855363 0.66 KDM4E (0.50) LATS1LATS2CCNB2CDK1CCNB1
SCHEMBL30324482 0.66 KDM4E (0.50) LATS1LATS2CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903992-A1 7-AZAINDOL-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMORS Merck Patent GmbH (DE) 2015-08-12 EP claimed
WO-2014053208-A1 7-AZAINDOL-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMORS MERCK PATENT GMBH (DE) 2014-04-10 WO claimed
US-9382244-B2 7-azaindole-2,7-naphthyridine derivative for the treatment of tumours MERCK PATENT GMBH (DE) 2016-07-05 US disclosed
US-20150252041-A1 7-AZAINDOLE-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMOURS MERCK PATENT GMBH (DE) 2015-09-10 US disclosed
EP-2903992-A1 7-AZAINDOL-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMORS Merck Patent GmbH (DE) 2015-08-12 EP disclosed
EP-2903992-A1 7-AZAINDOL-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMORS Merck Patent GmbH (DE) 2015-08-12 EP disclosed
WO-2014053208-A1 7-AZAINDOL-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMORS MERCK PATENT GMBH (DE) 2014-04-10 WO disclosed
WO-2014053208-A1 7-AZAINDOL-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMORS MERCK PATENT GMBH (DE) 2014-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252041-A1 7-AZAINDOLE-2,7-NAPHTHYRIDINE DERIVATIVE FOR THE TREATMENT OF TUMOURS MKI67, TK2, TYMP LATS1 129/4885LATS2 83/4885GRM4 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.